The Latest: Southeast Asian Patients Benefit From COVID-19 Innovation
Since the beginning of the COVID-19 pandemic, biopharmaceutical companies have found innovative ways to combat the global health crisis through unprecedented collaboration and partnerships, strengthened intellectual property rights and advanced research and development (R&D) processes. Innovators responded quickly by leveraging decades of existing research and scientific knowledge and building a robust innovation ecosystem that have since lead to several approved COVID-19 vaccines and treatments. As distribution continues to ramp up, patients throughout Southeast Asia are feeling the benefits of this biopharmaceutical investment and innovation.
Intellectual Property Rights Are Vital To COVID-19 Research and Development
A recent report from the Geneva Network is highlighting the important role intellectual property (IP) has played throughout the COVID-19 pandemic, encouraging public-private partnerships, enabling global knowledge-sharing and promoting innovative collaboration.
2020 Year in Review: COVID-19 Innovation
The COVID-19 pandemic may have disrupted most aspects of life this year, but it has also spurred unprecedented innovation. Backed by strong intellectual property protections, innovative biopharmaceutical companies were able to respond to the pandemic swiftly and utilize decades of research and development efforts on viruses similar to COVID-19 to develop vaccines and therapies in record time.
ICYMI: Regional leaders commit to fostering an innovation ecosystem throughout Southeast Asia
Regional leaders recently convened for two critical meetings – the 27th annual APEC Economic Leaders’ Meeting and the ASEAN Health Summit – to discuss various economic challenges imposed by the COVID-19 pandemic and its impact on the health of patients throughout Southeast Asia.